Ivermectin topical - Galderma

Drug Profile

Ivermectin topical - Galderma

Alternative Names: CD-5024; Rosiver; Soolantra

Latest Information Update: 08 Jan 2017

Price : $50

At a glance

  • Originator Galderma
  • Class Antiparasitics; Macrolides
  • Mechanism of Action Chloride channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rosacea
  • Phase II Acne vulgaris

Most Recent Events

  • 02 Nov 2016 Galderma completed a phase II trial in Acne vulgaris in Germany (Topical) (EudraCT2016-000063-16)
  • 10 Jul 2016 Phase-II clinical trials in Acne vulgaris in Germany (Topical) (EudraCT2016-000063-16)
  • 20 Jul 2015 Registered for Rosacea in Canada (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top